Autolus Therapeutics plc
AUTL · NASDAQ
Bulios Fair Price
$1.23
35.9% downside
Current Price
$1.92
According to Bulios Fair Price, AUTL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Autolus Therapeutics plc (AUTL) is a biotechnology company focused on developing immunotherapeutic drugs for cancer treatment. Utilizing advanced technologies in the field of gene engineering and cell therapy, Autolus Therapeutics aims to develop innovative therapies that selectively target cancer cells and minimize the side effects of traditional treatment methods. The company focuses on developing personalized treatment approaches that take into account individual genetic characteristics of patients. With its commitment to research and development, Autolus Therapeutics offers hope for new, effective therapeutic options in the fight against cancer. Autolus Therapeutics plc (AUTL) shares could be suitable for investors looking for investments in biotechnology with an emphasis on innovative cancer treatment.
Sector
Healthcare
Industry
Biotechnology
CEO
Christian Martin Itin
Employees
752
Headquarters
London
Upcoming events
Earnings
Upcoming earnings report